Collaborative Research, Development and License Agreement Sample Contracts
AMONGCollaborative Research, Development and License Agreement • December 21st, 2000 • Acadia Pharmaceuticals Inc • California
EX-10.1 2 d938892dex101.htm EX-10.1 Exhibit No. 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and...Collaborative Research, Development and License Agreement • May 5th, 2020 • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of June 11, 2003 (the “Effective Date”), by and between CURIS, INC., a Delaware corporation (“Curis”), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and GENENTECH, INC., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Between RENOVIS, INC. and GENENTECH, INC.Collaborative Research, Development and License Agreement • February 3rd, 2004 • Renovis Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of December 31, 2003 (the “Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”), with offices at Two Corporate Drive, South San Francisco, CA 94080, and GENENTECH, INC., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Renovis and Genentech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT between TARGACEPT, INC. and DR. FALK PHARMA GmbHCollaborative Research, Development and License Agreement • December 15th, 2004 • Targacept Inc • Pharmaceutical preparations • New York
This Collaborative Research, Development and License Agreement (this “Agreement”) is made and entered into as of January 26, 2001, by and between Targacept, Inc., a Delaware corporation having its principal place of business at 950 Reynolds Boulevard, Winston-Salem, North Carolina 27105 (“Targacept”), and Dr. Falk Pharma GmbH, a corporation organized and existing under the laws of Germany having its place of business at Leinenweberstrasse 5, 79041 Freiburg, Germany (“Dr. Falk”) (each of Targacept and Dr. Falk, a “Party” and, collectively, the “Parties”).
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. and ALLERGAN SALES, LLCCollaborative Research, Development and License Agreement • May 25th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of March 27, 2003 (the “Effective Date”) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively “Allergan”), both having offices at 2525 Dupont Drive, Irvine, California 92612.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Between CURIS, INC. and GENENTECH, INC.Collaborative Research, Development and License Agreement • July 10th, 2003 • Curis Inc • Biological products, (no disgnostic substances) • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of June 11, 2003 (the “Effective Date”), by and between CURIS, INC., a Delaware corporation (“Curis”), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and GENENTECH, INC., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
March 22, 2019Collaborative Research, Development and License Agreement • March 26th, 2019 • Curis Inc • Biological products, (no disgnostic substances)
SECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CURIS AND GENENTECHCollaborative Research, Development and License Agreement • April 19th, 2005 • Curis Inc • Biological products, (no disgnostic substances)
This Second Amendment (the “Amendment”), effective as of April 11, 2005 (the “Amendment Date”), is made by and between Curis, Inc., a Delaware corporation (“Curis”), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and Genentech, Inc., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT between ARQULE, INC. and DAIICHI SANKYO CO., LTD November 7, 2008Collaborative Research, Development and License Agreement • March 6th, 2009 • Arqule Inc • Pharmaceutical preparations • Massachusetts
This COLLABORATIVE RESEARCH DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of November 7, 2008, by and between ARQULE, Inc., a Delaware corporation with offices at 19 Presidential Way, Woburn, MA 01801-5140 (“ARQULE”), and Daiichi Sankyo Co., Ltd, a Japanese company organized under the laws of Japan with offices at 3-5-1 Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan (“DS”). Each of DS and ARQULE is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
AMENDMENT TO AND LICENSE AGREEMENTCollaborative Research, Development and License Agreement • June 5th, 2013 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS AMENDMENT TO 1999 COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is entered into as of May 31, 2013 (the “Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC (FKA ALLERGAN SALES, INC.), a limited liability company organized in the State of California, with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a company incorporated in the State of Delaware, with offices at 2525 Dupont Drive, Irvine, CA 92612 (hereinafter collectively, “Allergan”).
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4),Collaborative Research, Development and License Agreement • February 27th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT by and among ACADIA PHARMACEUTICALS INC., VISION PHARMACEUTICALS L.P. and ALLERGAN, INC.Collaborative Research, Development and License Agreement • May 25th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of September 24, 1997 (the “Effective Date”) by and between ACADIA PHARMACEUTICALS INC. (previously known as Receptor Technologies, Inc.), a Delaware corporation (“ACADIA”) with offices at 276 East Allen, Winooski, VT 05404, VISION PHARMACEUTICALS L.P., a Texas limited partnership (“Allergan”), with offices at 2525 Dupont Drive, Irvine, CA 92623 and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Vision Pharmaceuticals L.P.
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. and ALLERGAN SALES, LLCCollaborative Research, Development and License Agreement • February 27th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of March 27, 2003 (the “Effective Date”) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively “Allergan”), both having offices at 2525 Dupont Drive, Irvine, California 92612.
CONSENT AND ACKNOWLEDGEMENT OF PAYMENT DIRECTIONCollaborative Research, Development and License Agreement • March 13th, 2013 • Curis Inc • Biological products, (no disgnostic substances)
THIRD AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTSCollaborative Research, Development and License Agreement • May 5th, 2008 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
THIS THIRD AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (the “Third Amendment”) is entered into as of March 3, 2008 (the “Third Amendment Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES, LLC, a Delaware limited liability company (“Allergan”) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.
SECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTCollaborative Research, Development and License Agreement • March 15th, 2006 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS SECOND AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the “Second Amendment”) is entered into as of February 28, 2006 (the “Second Amendment Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES LLC a Delaware limited liability company, (“Allergan”), with offices at 2525 Dupont Drive, Irvine, CA 92623, and ALLERGAN, INC., a Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan.
Re: Collaborative Research, Development and License Agreement: Consent and Payment DirectionCollaborative Research, Development and License Agreement • March 9th, 2017 • Curis Inc • Biological products, (no disgnostic substances)
As we have discussed, Curis, Inc., a Delaware corporation (“Curis”), is in the process of discussing, under confidentiality agreements, a potential refinancing of the existing debt financing (the “Transaction”) of Curis Royalty LLC, a wholly owned subsidiary of Curis (the “Borrower”) by HealthCare Royalty Partners III, L.P. (the “Investor”), where the debt would be secured by the Borrower’s rights to receive certain payments under that certain Collaborative Research, Development and License Agreement, dated as of June 11, 2003, by and between Curis and Genentech, Inc. (“Genentech”), as amended as of December 10, 2004, April 11, 2005, May 8, 2006 and again as of April 26, 2012 (the “License Agreement”). As noted below, you have previously consented to the assignment of certain payment rights under the License Agreement from Curis to the Borrower. In connection with the Transaction, by this letter agreement (“Letter Agreement”), Curis is seeking Genentech’s consent under Section 16.8 of
AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTCollaborative Research, Development and License Agreement • January 14th, 2011 • Arqule Inc • Pharmaceutical preparations
This AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is entered into as of October 8, 2010 (the “Effective Date”) by and between ArQule, Inc. and Daiichi Sankyo Co., Ltd. (collectively, the “Parties”).
RECITALSCollaborative Research, Development and License Agreement • September 5th, 2000 • Elitra Pharmaceuticals Inc • New York
AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTCollaborative Research, Development and License Agreement • November 9th, 2010 • Arqule Inc • Pharmaceutical preparations
This AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is entered into as of October 8, 2010 (the “Effective Date”) by and between ArQule, Inc. and Daiichi Sankyo Co., Ltd. (collectively, the “Parties”).
FIRST AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CURIS AND GENENTECHCollaborative Research, Development and License Agreement • March 15th, 2005 • Curis Inc • Biological products, (no disgnostic substances)
This First Amendment (the “Amendment”), effective as of December 10, 2004 (the “Amendment Date”), is made by and between Curis, Inc., a Delaware corporation (“Curis”), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and Genentech, Inc., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT Among ACADIA PHARMACEUTICALS INC., and ALLERGAN, INC. and ALLERGAN PHARMACEUTICALS (IRELAND) LIMITED, INC. and ALLERGAN SALES, INC.Collaborative Research, Development and License Agreement • May 25th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of July 26, 1999 (the “Effective Date”) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121 and ALLERGAN PHARMACEUTICALS (IRELAND) LIMITED, INC. a Panamanian corporation with offices at Castlebar road Westport, County Mayo, Ireland, ALLERGAN SALES, INC. a California corporation with offices at 2525 Dupont Drive, Irvine, California 92612 and ALLERGAN, INC., a Delaware corporation, with offices at 2525 Dupont Drive, Irvine, California 92612 (hereinafter collectively “Allergan”),